V. van Dooren

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

D. Serie, E. Perez, E. Thompson, 2022, NPJ breast cancer.

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

D. Serie, E. Perez, E. Thompson, 2022, npj Breast Cancer.

18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO

Eileen Holmes, Patrick Flamen, Camilo Garcia, 2013, The Journal of Nuclear Medicine.

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

R. Coombes, M. Climent, U. Dafni, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

R. Gelber, M. Piccart, J. Baselga, 2019, Clinical breast cancer.